Dare Bioscience Announces Interim Safety And Efficacy Results From Phase 3 Clinical Trial Of Ovaprene

Second Positive DSMB Review Supports Continued Study Progress

Interim Phase 3 Results Support Ovaprene's Differentiation as a First-in-Category, Hormone-Free, Intravaginal Monthly Contraceptive